We are live on ! Find out more
JANX icon

Janux Therapeutics
JANX

46 hedge funds and large institutions have $542M invested in Janux Therapeutics in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 9

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

2.4% more ownership

Funds ownership: 63.68% → 66.08% (+2.4%)

2% more funds holding

Funds holding: 45 → 46 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less capital invested

Capital invested by funds: $571M → $542M (-$29.6M)

Holders
46
Holders Change
+1
Holders Change %
+2.22%
% of All Funds
0.71%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
19
Reduced
9
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$28.8M
2
BlackRock
BlackRock
New York
+$4.33M
3
Cerity Partners
Cerity Partners
New York
+$3.16M
4
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale
Germany
+$943K
5
State Street
State Street
Massachusetts
+$774K

Top Sellers

1
O
OrbiMed
New York
-$13.2M
2
SG Americas Securities
SG Americas Securities
New York
-$1.42M
3
LGM
Logos Global Management
California
-$1.3M
4
PPA
Parametric Portfolio Associates
Washington
-$1.28M
5
Janney Montgomery Scott
Janney Montgomery Scott
Pennsylvania
-$884K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$171M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$98.5M +$28.8M +1,375,971 +38%
O
3
OrbiMed
New York
$56M -$13.2M -630,000 -18%
Janus Henderson Group
4
Janus Henderson Group
United Kingdom
$46.6M -$325K -15,511 -0.6%
Citadel Advisors
5
Citadel Advisors
Florida
$36.6M -$122K -5,814 -0.3%
EC
6
EcoR1 Capital
California
$27.9M – – –
BI
7
BVF Inc
California
$20.1M – – –
BlackRock
8
BlackRock
New York
$19.9M +$4.33M +206,483 +26%
Vanguard Group
9
Vanguard Group
Pennsylvania
$10.5M +$59.3K +2,829 +0.5%
5VM
10
5AM Venture Management
California
$8.8M – – –
SB
11
Samsara BioCapital
California
$8.13M – – –
Adage Capital Partners
12
Adage Capital Partners
Massachusetts
$7.89M – – –
WP
13
Woodline Partners
California
$5.49M -$456K -21,756 -7%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$4.35M +$181K +8,647 +4%
State Street
15
State Street
Massachusetts
$4.17M +$774K +36,922 +21%
LGM
16
Logos Global Management
California
$3.65M -$1.3M -61,926 -25%
Cerity Partners
17
Cerity Partners
New York
$2.98M +$3.16M +150,933 New
Northern Trust
18
Northern Trust
Illinois
$2.28M -$30.7K -1,466 -1%
DekaBank Deutsche Girozentrale
19
DekaBank Deutsche Girozentrale
Germany
$892K +$943K +45,000 New
Bank of New York Mellon
20
Bank of New York Mellon
New York
$721K +$106K +5,064 +16%
Charles Schwab
21
Charles Schwab
California
$670K +$28.7K +1,370 +4%
PL
22
Parkwood LLC
Ohio
$634K +$238K +11,351 +55%
D.E. Shaw & Co
23
D.E. Shaw & Co
New York
$548K -$385K -18,385 -40%
N
24
Nuveen
North Carolina
$345K – – –
Jane Street
25
Jane Street
New York
$311K +$330K +15,746 New
1
2 3

JANX Hedge Fund Activity: Q4 2021 in Review

46 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q4 2021, worth a combined $542M — down 5.2% from $571M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new JANX positions and 5 closed out — a net gain of 1 holder — while 19 added to existing stakes and 9 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $28.8M. The largest seller was OrbiMed, cutting an estimated $13.2M.

  • 46 institutional investors held Janux Therapeutics (JANX) as of Q4 2021, up from 45 in Q3 2021.
  • Funds reported $542M of Janux Therapeutics stock for Q4 2021, down 5.2% quarter-over-quarter.
  • 6 funds opened new Janux Therapeutics positions in Q4 2021 and 5 closed out, a net change of +1 holder.
  • The largest Janux Therapeutics buyer in Q4 2021 was Fidelity Investments, an estimated $28.8M added.
  • The largest Janux Therapeutics seller in Q4 2021 was OrbiMed, an estimated $13.2M sold.

Based on aggregated 13F filings for Q4 2021.